We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer

News   May 24, 2013

 
Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer
 
 
 

RELATED ARTICLES

Patent Issued for Osteoarthritis Gene Therapy Product

News

A potentially disease-modifying therapy for osteoarthritis has reached a key milestone now that a U.S. patent has been issued for FX201, a gene-therapy product candidate based on work led by Baylor College of Medicine researchers.

READ MORE

Molecular “Handshake” Causes T Cells to Leave Tumors Alone

News

Researchers at ETH Zurich have discovered redundancies in the biochemical signalling pathways of immune cells. This finding has important implications for advances in cancer immunotherapy, among other areas.

READ MORE

Stage Set for Uncovering Multiple Autoimmune Drug Targets

News

The identification of molecular signatures that reflect the pathology of lupus and arthritis provide new insights into tissue damage, and set the stage for uncovering potential drug target candidates.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE